higher costs particularly raw material costs impacted the EBITDA result compared to the same period in 2016. Fuel prices have risen however, as prices were agreed before the latest spike, the company paid
related corporate tax transaction, the normalized net profit would be approximately THB 97.42 million or a surge of 48% yoy. Page 3 of 4 Statement of Financial Position as of March 31, 2019 The consolidated
March 2018 increased by 19% yoy mainly from the surge of provisions for employee benefit and other liabilities. Most of the increase of other liabilities was income tax payable on 2017 profit because
device sales to decline significantly. The main cause for the decline is the surge in IT devices demand during the COVID-19. Consumers had purchased a large number of IT products such as laptops, tablets
คาดว่า จะเกิดขึ้นจริง เช่น หากมีผู้ใช้งานเข้ามาใช้ระบบพร้อมกัน 100 คน ระบบจะตอบสนองเร็วหรือช้าแค่ไหน (ข) Spike testing คือ การทดสอบระบบเมื่อมีการเพ่ิมจำนวนผู้ใช้งานอย่างรวดเร็ว (ค) Endurance testing คือ
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
administrative expenses for the three months period ended 31 March 2018 and 2019 at THB 34.11 million and THB 40.14 million respectively. This equals to a surge of 17.68 % in administrative expenses year on year
& expenses (net of tax) from the comparing quarters, the normalized net profit would be approximately THB 72.8 million in 2Q19 comparing to THB 52.4 million in 2Q18 or a surge of 39% . Statement of Financial